Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

• Status: Active, not recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in patients with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea University Guro Hospital
• Collaborator: Chong Kun Dang Pharmaceutical Corp.

Criteria

Inclusion Criteria:

1. Males or females ≥ 19 years of age

2. Non Small Cell Lung Cancer(Non-Squamous Cell Carcinoma) patients who had shown clinical benefits (Complete response(CR) or Partial response(PR) or Stable disease(SD) ≥6 months) from EGFR-TKIs as first line treatment and developed progressive disease, and then received cytotoxic chemotherapy more than 4 cycles and developed progressive disease, and then confirmed T790 negative and sensitizing EGFR mutation(E19Del, L858R, L861Q, G719X, E19insertion) positive in Histologic, cytologic specimen or blood.

3. Patient with at least one measurable lesions according to RECIST v 1.1

4. Expected life expectancy ≥ 12 weeks

5. Eastern Cooperative Oncology Group(ECOG) performance status ≤ 2

6. Patients who have proper hematologic, renal and hepatic functions as follows:

• Absolute neutrophil count(ANC) ≥ 1,500/mm³

• platelets ≥ 100,000/mm³

• Hemoglobin ≥ 9g/dL

• Total bilirubin ≤ 1.25 X UNL

• Aspartate aminotransferase(AST or SGOT) and alanine aminotransferase(ALT or SGPT) ≤ 3.0 X UNL (if liver metastasis ≤5.0 X UNL)

• Alkaline phosphatase ≤ 2.5 X UNL (if liver metastasis ≤5.0 X UNL)

• Serum creatinine ≤ 1.5mg/dL

7. patients who are willing to comply with study procedure and voluntarily provide informed consent with signature

Exclusion Criteria:

1. Patients who have preexisting or coexisting malignancies in other parts except for effectively treated non-melanoma skin cancer, cervical carcinoma in situ(CIS) cervical cancer within the last 5 years

2. Patients with brain metastasis except for the followings:

• Asymptomatic and stable brain metastases for which local treatment has been given:

corticosteroids treatment isn't requiured for at least 2 weeks before starting the study treatment.

3. Patients currently receiving palliative radiation therapy or have toxicities from radiation therapy at screening.

4. Patients with clinically active history of interstitial lung disease(ILD), Drug induced ILD, Radiation pneumonitis

5. Patients with clinically significant cardiovascular disease or myocardial infarction within the past 12 months.

6. Patients with active infection or severe systemic disease that are difficult to include in this study

7. Patients who received radiation therapy to target lesion of this study.

8. Patients who had major operation within 4 weeks before starting the study treatment and were not fully recovered.

9. Patients who were administered other study drugs within 4 weeks before starting the study treatment

10. Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive pregnancy test prior to study entry

11. Patients who are difficult to include in this study in accordance with the investigator's judgment

12. Patients with histories of hypersensitivity to investigational product(IP) or any components of the agent

13. Patients with any of the following genetic predispositions including galactose intolerance, Lapp lactase deficiency, lactose intolerance or glucose-galactose malabsorption

14. Patient previously received cytotoxic chemotherapy within 2 weeks of IP administration

15. Patient received Immunotherapy prior to the study participation

16. Patients who are difficult to include in this study in accordance with the investigator's judgment due to severe adverse effects during previous EGFR TKI treatment